Abstract
Myotonic dystrophy is one of the most common dominant neuromuscular disorders that results in muscle dysfunction. Myotonic dystrophy type 1 (DM1) or Steinert’s disease is caused by an expanded CTG repeats in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene, whereas myotonic dystrophy type (DM2) is caused by expanded CCTG repeats in the first intron of the CCHC-type zinc finger, nucleic acid-binding protein (CNBP) gene. The clinical manifestations worsen with each generation (anticipation) consistent with an expansion of the repeats. The tri- or tetranucleotide repeat expansion results in gain-of-function pathogenic RNAs which are retained in the nuclei and sequester RNA-binding proteins such as MBNL and CUGBP that interfere with splicing. Unfortunately, there is currently no cure available for these dominant neuromuscular diseases. Nevertheless, some promising therapeutic strategies have been developed that are aimed at directly tackling the genetic cause of the disease. In particular, antisense oligonucleotide technologies, gene therapy, and gene editing or small molecules are being explored. Recently, a phase 1/2a clinical trial has been completed that is based on the premise of promoting RNase-H-mediated degradation of the expanded CUG transcripts using antisense oligonucleotides. In this review, we summarize the current progress on different cellular and animal models as well as various therapeutic strategies for DM with specific emphasis on gene therapy and gene editing approaches using TALENs and CRISPR/Cas9. Lastly, translational challenges and future promising therapeutic avenues are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Musova Z, Mazanec R, Krepelova A, Ehler E, Vales J, Jaklova R, Prochazka T, Koukal P, Marikova T, Kraus J, Havlovicova M, Sedlacek Z (2009) Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene. Am J Med Genet A 149A(7):1365–1374. https://doi.org/10.1002/ajmg.a.32987
Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11(10):891–905. https://doi.org/10.1016/S1474-4422(12)70204-1
Mathieu J, De Braekeleer M, Prevost C (1990) Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 40(5):839–842
Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255(5049):1256–1258
Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O’Hoy K et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science 255(5049):1253–1255
Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 68(4):799–808
Savic Pavicevic D, Miladinovic J, Brkusanin M, Svikovic S, Djurica S, Brajuskovic G, Romac S (2013) Molecular genetics and genetic testing in myotonic dystrophy type 1. Biomed Res Int 2013:391821. https://doi.org/10.1155/2013/391821
Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL, Pascuzzi RM (2011) Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve 43(5):648–651. https://doi.org/10.1002/mus.21934
Barbe L, Lanni S, Lopez-Castel A, Franck S, Spits C, Keymolen K, Seneca S, Tome S, Miron I, Letourneau J, Liang M, Choufani S, Weksberg R, Wilson MD, Sedlacek Z, Gagnon C, Musova Z, Chitayat D, Shannon P, Mathieu J, Sermon K, Pearson CE (2017) CpG methylation, a parent-of-origin effect for maternal-biased transmission of congenital myotonic dystrophy. Am J Hum Genet 100(3):488–505. https://doi.org/10.1016/j.ajhg.2017.01.033
Harper PS, Harley HG, Reardon W, Shaw DJ (1992) Anticipation in myotonic dystrophy: new light on an old problem. Am J Hum Genet 51(1):10–16
Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes JP, Duros C, Savoy D, Dehaupas I, Luce S, Johnson K, Junien C (1993) Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am J Hum Genet 52(5):875–883
Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293(5531):864–867. https://doi.org/10.1126/science.1062125
Liquori CL, Ikeda Y, Weatherspoon M, Ricker K, Schoser BG, Dalton JC, Day JW, Ranum LP (2003) Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 73(4):849–862. https://doi.org/10.1086/378720
Kurosaki T, Ueda S, Ishida T, Abe K, Ohno K, Matsuura T (2012) The unstable CCTG repeat responsible for myotonic dystrophy type 2 originates from an AluSx element insertion into an early primate genome. PLoS One 7(6):e38379. https://doi.org/10.1371/journal.pone.0038379
Guo P, Lam SL (2015) New insights into the genetic instability in CCTG repeats. FEBS Lett 589(20 Pt B):3058–3063. https://doi.org/10.1016/j.febslet.2015.09.007
Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, Peltonen L, Krahe R, Udd B (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19(7):776–782. https://doi.org/10.1038/ejhg.2011.23
Harper PS (2001) The genetic basis of myotonic dystrophy. In: Harper PS (ed) Myotonic dystrophy, 3rd edn. W.B. Saunders, London, pp 307–363
Bellini M, Biagi S, Stasi C, Costa F, Mumolo MG, Ricchiuti A, Marchi S (2006) Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol 12(12):1821–1828
Meola G, Cardani R (2017) Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci 38(4):535–546. https://doi.org/10.1007/s10072-016-2805-5
Day JW, Ranum LP (2005) RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 15(1):5–16. https://doi.org/10.1016/j.nmd.2004.09.012
Renna LV, Cardani R, Botta A, Rossi G, Fossati B, Costa E, Meola G (2014) Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction. Eur J Histochem 58(4):2444. https://doi.org/10.4081/ejh.2014.2444
Bigot A, Klein AF, Gasnier E, Jacquemin V, Ravassard P, Butler-Browne G, Mouly V, Furling D (2009) Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am J Pathol 174(4):1435–1442. https://doi.org/10.2353/ajpath.2009.080560
Arsenault ME, Prevost C, Lescault A, Laberge C, Puymirat J, Mathieu J (2006) Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 66(8):1248–1250. https://doi.org/10.1212/01.wnl.0000208513.48550.08
Serra L, Mancini M, Silvestri G, Petrucci A, Masciullo M, Spano B, Torso M, Mastropasqua C, Giacanelli M, Caltagirone C, Cercignani M, Meola G, Bozzali M (2016) Brain connectomics’ modification to clarify motor and nonmotor features of myotonic dystrophy type 1. Neural Plast 2016:2696085. https://doi.org/10.1155/2016/2696085
Denis JA, Gauthier M, Rachdi L, Aubert S, Giraud-Triboult K, Poydenot P, Benchoua A, Champon B, Maury Y, Baldeschi C, Scharfmann R, Pietu G, Peschanski M, Martinat C (2013) mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1. J Cell Sci 126(Pt 8):1763–1772. https://doi.org/10.1242/jcs.116285
Ho G, Cardamone M, Farrar M (2015) Congenital and childhood myotonic dystrophy: current aspects of disease and future directions. World J Clin Pediatr 4(4):66–80. https://doi.org/10.5409/wjcp.v4.i4.66
Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE (1997) Expansion of a CUG trinucleotide repeat in the 3’ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci U S A 94(14):7388–7393
Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH (1995) Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 128(6):995–1002
Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289(5485):1769–1773
Seznec H, Agbulut O, Sergeant N, Savouret C, Ghestem A, Tabti N, Willer JC, Ourth L, Duros C, Brisson E, Fouquet C, Butler-Browne G, Delacourte A, Junien C, Gourdon G (2001) Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet 10(23):2717–2726
Michalowski S, Miller JW, Urbinati CR, Paliouras M, Swanson MS, Griffith J (1999) Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein. Nucleic Acids Res 27(17):3534–3542
Mooers BH, Logue JS, Berglund JA (2005) The structural basis of myotonic dystrophy from the crystal structure of CUG repeats. Proc Natl Acad Sci U S A 102(46):16626–16631. https://doi.org/10.1073/pnas.0505873102
Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19(17):4439–4448. https://doi.org/10.1093/emboj/19.17.4439
Tian B, White RJ, Xia T, Welle S, Turner DH, Mathews MB, Thornton CA (2000) Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA 6(1):79–87
Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS (2003) A muscleblind knockout model for myotonic dystrophy. Science 302(5652):1978–1980. https://doi.org/10.1126/science.1088583
Charizanis K, Lee KY, Batra R, Goodwin M, Zhang C, Yuan Y, Shiue L, Cline M, Scotti MM, Xia G, Kumar A, Ashizawa T, Clark HB, Kimura T, Takahashi MP, Fujimura H, Jinnai K, Yoshikawa H, Gomes-Pereira M, Gourdon G, Sakai N, Nishino S, Foster TC, Ares M Jr, Darnell RB, Swanson MS (2012) Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 75(3):437–450. https://doi.org/10.1016/j.neuron.2012.05.029
Hao M, Akrami K, Wei K, De Diego C, Che N, Ku JH, Tidball J, Graves MC, Shieh PB, Chen F (2008) Muscleblind-like 2 (Mbnl2) -deficient mice as a model for myotonic dystrophy. Dev Dyn 237(2):403–410. https://doi.org/10.1002/dvdy.21428
Lee KY, Li M, Manchanda M, Batra R, Charizanis K, Mohan A, Warren SA, Chamberlain CM, Finn D, Hong H, Ashraf H, Kasahara H, Ranum LP, Swanson MS (2013) Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med 5(12):1887–1900. https://doi.org/10.1002/emmm.201303275
Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA (2008) A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 105(51):20333–20338. https://doi.org/10.1073/pnas.0809045105
Konieczny P, Stepniak-Konieczna E, Sobczak K (2015) MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res 42(17):10873–10887. https://doi.org/10.1093/nar/gku767
Kanadia RN, Urbinati CR, Crusselle VJ, Luo D, Lee YJ, Harrison JK, Oh SP, Swanson MS (2003) Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3. Gene Expr Patterns 3(4):459–462
Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, Swanson MS, Thornton CA (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15(13):2087–2097. https://doi.org/10.1093/hmg/ddl132
Dansithong W, Paul S, Comai L, Reddy S (2005) MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem 280(7):5773–5780. https://doi.org/10.1074/jbc.M410781200
Kino Y, Washizu C, Kurosawa M, Oma Y, Hattori N, Ishiura S, Nukina N (2015) Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. Hum Mol Genet 24(3):740–756. https://doi.org/10.1093/hmg/ddu492
Michel L, Huguet-Lachon A, Gourdon G (2015) Sense and antisense DMPK RNA foci accumulate in DM1 tissues during development. PLoS One 10(9):e0137620. https://doi.org/10.1371/journal.pone.0137620
Iyer D, Belaguli N, Fluck M, Rowan BG, Wei L, Weigel NL, Booth FW, Epstein HF, Schwartz RJ, Balasubramanyam A (2003) Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. Biochemistry 42(24):7477–7486. https://doi.org/10.1021/bi030045n
Lee MY, Park C, Ha SE, Park PJ, Berent RM, Jorgensen BG, Corrigan RD, Grainger N, Blair PJ, Slivano OJ, Miano JM, Ward SM, Smith TK, Sanders KM, Ro S (2017) Serum response factor regulates smooth muscle contractility via myotonic dystrophy protein kinases and L-type calcium channels. PLoS One 12(2):e0171262. https://doi.org/10.1371/journal.pone.0171262
Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, Snider L, Yuen EC, Soriano P, Tapscott SJ (2000) Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat Genet 25(1):105–109. https://doi.org/10.1038/75490
Sarkar PS, Appukuttan B, Han J, Ito Y, Ai C, Tsai W, Chai Y, Stout JT, Reddy S (2000) Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts. Nat Genet 25(1):110–114. https://doi.org/10.1038/75500
Wakimoto H, Maguire CT, Sherwood MC, Vargas MM, Sarkar PS, Han J, Reddy S, Berul CI (2002) Characterization of cardiac conduction system abnormalities in mice with targeted disruption of Six5 gene. J Interv Card Electrophysiol 7(2):127–135
Personius KE, Nautiyal J, Reddy S (2005) Myotonia and muscle contractile properties in mice with SIX5 deficiency. Muscle Nerve 31(4):503–505. https://doi.org/10.1002/mus.20239
Rhodes JD, Lott MC, Russell SL, Moulton V, Sanderson J, Wormstone IM, Broadway DC (2012) Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts. Hum Mol Genet 21(4):852–862. https://doi.org/10.1093/hmg/ddr515
Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT 3rd, Thornton CA (2013) Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol 74(6):862–872. https://doi.org/10.1002/ana.23992
Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10(1):45–53
Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10(1):35–44
Fugier C, Klein AF, Hammer C, Vassilopoulos S, Ivarsson Y, Toussaint A, Tosch V, Vignaud A, Ferry A, Messaddeq N, Kokunai Y, Tsuburaya R, de la Grange P, Dembele D, Francois V, Precigout G, Boulade-Ladame C, Hummel MC, de Munain AL, Sergeant N, Laquerriere A, Thibault C, Deryckere F, Auboeuf D, Garcia L, Zimmermann P, Udd B, Schoser B, Takahashi MP, Nishino I, Bassez G, Laporte J, Furling D, Charlet-Berguerand N (2011) Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 17(6):720–725. https://doi.org/10.1038/nm.2374
Tang ZZ, Yarotskyy V, Wei L, Sobczak K, Nakamori M, Eichinger K, Moxley RT, Dirksen RT, Thornton CA (2012) Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet 21(6):1312–1324. https://doi.org/10.1093/hmg/ddr568
Rau F, Lainé J, Ramanoudjame L, Ferry A, Arandel L, Delalande O, Jollet A, Dingli F, Lee K-Y, Peccate C, Lorain S, Kabashi E, Athanasopoulos T, Koo T, Loew D, Swanson MS, Le Rumeur E, Dickson G, Allamand V, Marie J, Furling D (2015) Abnormal splicing switch of DMD’s penultimate exon compromises muscle fiber maintenance in myotonic dystrophy. Nat Commun 6:7205
Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29(1):40–47. https://doi.org/10.1038/ng704
Sergeant N, Sablonniere B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A (2001) Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 10(19):2143–2155
Rau F, Freyermuth F, Fugier C, Villemin JP, Fischer MC, Jost B, Dembele D, Gourdon G, Nicole A, Duboc D, Wahbi K, Day JW, Fujimura H, Takahashi MP, Auboeuf D, Dreumont N, Furling D, Charlet-Berguerand N (2011) Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 18(7):840–845. https://doi.org/10.1038/nsmb.2067
Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 119(12):3797–3806. https://doi.org/10.1172/JCI37976
Kuyumcu-Martinez NM, Wang GS, Cooper TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28(1):68–78. https://doi.org/10.1016/j.molcel.2007.07.027
Dansithong W, Jog SP, Paul S, Mohammadzadeh R, Tring S, Kwok Y, Fry RC, Marjoram P, Comai L, Reddy S (2011) RNA steady-state defects in myotonic dystrophy are linked to nuclear exclusion of SHARP. EMBO Rep 12(7):735–742. https://doi.org/10.1038/embor.2011.86
Gladman JT, Yadava RS, Mandal M, Yu Q, Kim YK, Mahadevan MS (2015) NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity. Hum Mol Genet 24(1):251–264. https://doi.org/10.1093/hmg/ddu443
Laurent FX, Sureau A, Klein AF, Trouslard F, Gasnier E, Furling D, Marie J (2012) New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats. Nucleic Acids Res 40(7):3159–3171. https://doi.org/10.1093/nar/gkr1228
Ravel-Chapuis A, Belanger G, Yadava RS, Mahadevan MS, DesGroseillers L, Cote J, Jasmin BJ (2012) The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing. J Cell Biol 196(6):699–712. https://doi.org/10.1083/jcb.201108113
Yadava RS, Frenzel-McCardell CD, Yu Q, Srinivasan V, Tucker AL, Puymirat J, Thornton CA, Prall OW, Harvey RP, Mahadevan MS (2008) RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet 40(1):61–68. https://doi.org/10.1038/ng.2007.28
Bondy-Chorney E, Crawford Parks TE, Ravel-Chapuis A, Klinck R, Rocheleau L, Pelchat M, Chabot B, Jasmin BJ, Cote J (2016) Staufen1 regulates multiple alternative splicing events either positively or negatively in DM1 indicating its role as a disease modifier. PLoS Genet 12(1):e1005827. https://doi.org/10.1371/journal.pgen.1005827
Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, Donohue JP, Hall MP, Shiue L, Swanson MS, Thornton CA, Ares M Jr (2010) Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 17(2):187–193. https://doi.org/10.1038/nsmb.1720
Osborne RJ, Lin X, Welle S, Sobczak K, O’Rourke JR, Swanson MS, Thornton CA (2009) Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 18(8):1471–1481. https://doi.org/10.1093/hmg/ddp058
Perfetti A, Greco S, Fasanaro P, Bugiardini E, Cardani R, Garcia-Manteiga JM, Riba M, Cittaro D, Stupka E, Meola G, Martelli F (2014) Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2. PLoS One 9(4):e93983. https://doi.org/10.1371/journal.pone.0093983
Bachinski LL, Baggerly KA, Neubauer VL, Nixon TJ, Raheem O, Sirito M, Unruh AK, Zhang J, Nagarajan L, Timchenko LT, Bassez G, Eymard B, Gamez J, Ashizawa T, Mendell JR, Udd B, Krahe R (2014) Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies. Neuromuscul Disord 24(3):227–240. https://doi.org/10.1016/j.nmd.2013.11.001
An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM (2012) Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253–263. https://doi.org/10.1016/j.stem.2012.04.026
Mittelman D, Moye C, Morton J, Sykoudis K, Lin Y, Carroll D, Wilson JH (2009) Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A 106(24):9607–9612. https://doi.org/10.1073/pnas.0902420106
Olsen PA, Solhaug A, Booth JA, Gelazauskaite M, Krauss S (2009) Cellular responses to targeted genomic sequence modification using single-stranded oligonucleotides and zinc-finger nucleases. DNA Repair (Amst) 8(3):298–308. https://doi.org/10.1016/j.dnarep.2008.11.011
Richard GF, Viterbo D, Khanna V, Mosbach V, Castelain L, Dujon B (2014) Highly specific contractions of a single CAG/CTG trinucleotide repeat by TALEN in yeast. PLoS One 9(4):e95611. https://doi.org/10.1371/journal.pone.0095611
Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, Terada N, Ashizawa T, Xia G (2016) Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy. Mol Ther 24(8):1378–1387. https://doi.org/10.1038/mt.2016.97
Xia G, Gao Y, Jin S, Subramony S, Terada N, Ranum LP, Swanson MS, Ashizawa T (2015) Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 iPS-cell derived neural stem cells. Stem Cells 33(6):1829–1838. https://doi.org/10.1002/stem.1970
van Agtmaal EL, Andre LM, Willemse M, Cumming SA, van Kessel ID, van den Broek WJ, Gourdon G, Furling D, Mouly V, Monckton DG, Wansink DG, Wieringa B (2017) CRISPR/Cas9-induced (CTGCAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther 25(1):24–43. https://doi.org/10.1016/j.ymthe.2016.10.014
Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10(10):977–979. https://doi.org/10.1038/nmeth.2598
Furling D, Coiffier L, Mouly V, Barbet JP, St Guily JL, Taneja K, Gourdon G, Junien C, Butler-Browne GS (2001) Defective satellite cells in congenital myotonic dystrophy. Hum Mol Genet 10(19):2079–2087
Ketley A, Chen CZ, Li X, Arya S, Robinson TE, Granados-Riveron J, Udosen I, Morris GE, Holt I, Furling D, Chaouch S, Haworth B, Southall N, Shinn P, Zheng W, Austin CP, Hayes CJ, Brook JD (2014) High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Hum Mol Genet 23(6):1551–1562. https://doi.org/10.1093/hmg/ddt542
Gonzalez-Barriga A, Mulders SA, van de Giessen J, Hooijer JD, Bijl S, van Kessel ID, van Beers J, van Deutekom JC, Fransen JA, Wieringa B, Wansink DG (2013) Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids 2:e81. https://doi.org/10.1038/mtna.2013.9
Hernandez-Hernandez O, Guiraud-Dogan C, Sicot G, Huguet A, Luilier S, Steidl E, Saenger S, Marciniak E, Obriot H, Chevarin C, Nicole A, Revillod L, Charizanis K, Lee KY, Suzuki Y, Kimura T, Matsuura T, Cisneros B, Swanson MS, Trovero F, Buisson B, Bizot JC, Hamon M, Humez S, Bassez G, Metzger F, Buee L, Munnich A, Sergeant N, Gourdon G, Gomes-Pereira M (2013) Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain 136(Pt 3):957–970. https://doi.org/10.1093/brain/aws367
Hoskins JW, Ofori LO, Chen CZ, Kumar A, Sobczak K, Nakamori M, Southall N, Patnaik S, Marugan JJ, Zheng W, Austin CP, Disney MD, Miller BL, Thornton CA (2014) Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res 42(10):6591–6602. https://doi.org/10.1093/nar/gku275
Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT (2012) GSK3beta mediates muscle pathology in myotonic dystrophy. J Clin Invest 122(12):4461–4472. https://doi.org/10.1172/JCI64081
Arandel L, Polay-Espinosa M, Matloka M, Bazinet A, De Dea Diniz D, Naouar N, Rau F, Jollet A, Edom-Vovard F, Mamchaoui K, Tarnopolsky M, Puymirat J, Battail C, Boland A, Deleuze JF, Mouly V, Klein AF, Furling D (2017) Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. Dis Model Mech 10(4):487–497. https://doi.org/10.1242/dmm.027367
Du J, Campau E, Soragni E, Jespersen C, Gottesfeld JM (2013) Length-dependent CTG.CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells. Hum Mol Genet 22(25):5276–5287. https://doi.org/10.1093/hmg/ddt386
Gomes-Pereira M, Cooper TA, Gourdon G (2011) Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med 17(9):506–517. https://doi.org/10.1016/j.molmed.2011.05.004
Huguet A, Medja F, Nicole A, Vignaud A, Guiraud-Dogan C, Ferry A, Decostre V, Hogrel JY, Metzger F, Hoeflich A, Baraibar M, Gomes-Pereira M, Puymirat J, Bassez G, Furling D, Munnich A, Gourdon G (2012) Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genet 8(11):e1003043. https://doi.org/10.1371/journal.pgen.1003043
Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, Butler-Browne G, Puymirat J, Gourdon G, Furling D (2010) Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway. Neuromuscul Disord 20(5):319–325. https://doi.org/10.1016/j.nmd.2010.03.006
Gomes-Pereira M, Foiry L, Nicole A, Huguet A, Junien C, Munnich A, Gourdon G (2007) CTG trinucleotide repeat “big jumps”: large expansions, small mice. PLoS Genet 3(4):e52. https://doi.org/10.1371/journal.pgen.0030052
Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA (2007) Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 117(10):2802–2811. https://doi.org/10.1172/JCI32308
Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, Jin B, Sirito M, Sarkar P, Krahe R, Timchenko NA, Timchenko LT (2009) Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 175(2):748–762. https://doi.org/10.2353/ajpath.2009.090047
Chen W, Wang Y, Abe Y, Cheney L, Udd B, Li YP (2007) Haploinsuffciency for Znf9 in Znf9+/− mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol 368(1):8–17. https://doi.org/10.1016/j.jmb.2007.01.088
Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LP (2006) DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 15(11):1808–1815. https://doi.org/10.1093/hmg/ddl103
Raheem O, Olufemi SE, Bachinski LL, Vihola A, Sirito M, Holmlund-Hampf J, Haapasalo H, Li YP, Udd B, Krahe R (2010) Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. Am J Pathol 177(6):3025–3036. https://doi.org/10.2353/ajpath.2010.100179
Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75(1):280–284
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11(2):125–140. https://doi.org/10.1038/nrd3625
Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111–115. https://doi.org/10.1038/nature11362
Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP, Wancewicz EV, Witchell D, Swayze EE (2009) Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52(1):10–13. https://doi.org/10.1021/jm801294h
Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, Park SY, Zhou T, He G, Kim Y, MacLeod AR, Monia BP, Lio S, Kim TW, Henry SP (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther 23(3):213–227. https://doi.org/10.1089/nat.2013.0422
Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, Gattis D, Jauvin D, Puymirat J, Swayze EE, Freier SM, Bennett CF, Thornton CA, MacLeod AR (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355(2):329–340. https://doi.org/10.1124/jpet.115.226969
Wojtkowiak-Szlachcic A, Taylor K, Stepniak-Konieczna E, Sznajder LJ, Mykowska A, Sroka J, Thornton CA, Sobczak K (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43(6):3318–3331. https://doi.org/10.1093/nar/gkv163
Weiss B, Davidkova G, Zhou LW (1999) Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 55(3):334–358. https://doi.org/10.1007/s000180050296
Furling D, Doucet G, Langlois MA, Timchenko L, Belanger E, Cossette L, Puymirat J (2003) Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther 10(9):795–802. https://doi.org/10.1038/sj.gt.3301955
Francois V, Klein AF, Beley C, Jollet A, Lemercier C, Garcia L, Furling D (2011) Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol 18(1):85–87. https://doi.org/10.1038/nsmb.1958
Langlois MA, Boniface C, Wang G, Alluin J, Salvaterra PM, Puymirat J, Rossi JJ, Lee NS (2005) Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem 280(17):16949–16954. https://doi.org/10.1074/jbc.M501591200
Sobczak K, Wheeler TM, Wang W, Thornton CA (2013) RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther 21(2):380–387. https://doi.org/10.1038/mt.2012.222
Bisset DR, Stepniak-Konieczna EA, Zavaljevski M, Wei J, Carter GT, Weiss MD, Chamberlain JR (2015) Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet 24(17):4971–4983. https://doi.org/10.1093/hmg/ddv219
Sioud M (2004) Ribozyme- and siRNA-mediated mRNA degradation: a general introduction. Methods Mol Biol 252:1–8. https://doi.org/10.1385/1-59259-746-7:001
Fedor MJ, Williamson JR (2005) The catalytic diversity of RNAs. Nat Rev Mol Cell Biol 6(5):399–412. https://doi.org/10.1038/nrm1647
Phylactou LA, Darrah C, Wood MJ (1998) Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat Genet 18(4):378–381. https://doi.org/10.1038/ng0498-378
Langlois MA, Lee NS, Rossi JJ, Puymirat J (2003) Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 7(5 Pt 1):670–680
Choudhury R, Tsai YS, Dominguez D, Wang Y, Wang Z (2012) Engineering RNA endonucleases with customized sequence specificities. Nat Commun 3:1147. https://doi.org/10.1038/ncomms2154
Zhang W, Wang Y, Dong S, Choudhury R, Jin Y, Wang Z (2014) Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats. Mol Ther 22(2):312–320. https://doi.org/10.1038/mt.2013.251
Goyenvalle A, Davies KE (2011) Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle 1(1):8. https://doi.org/10.1186/2044-5040-1-8
Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F (2012) Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr Gene Ther 12(3):152–160
Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA (2007) Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117(12):3952–3957. https://doi.org/10.1172/JCI33355
Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325(5938):336–339. https://doi.org/10.1126/science.1173110
Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 106(33):13915–13920. https://doi.org/10.1073/pnas.0905780106
Wojtkowiak JW, Cornnell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, Kim M, Zhang X, Leos R, Bailey KM, Martinez G, Lloyd MC, Weber C, Mitchell JB, Lynch RM, Baker AF, Gatenby RA, Rejniak KA, Hart C, Krishna MC, Gillies RJ (2015) Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302. Cancer Metab 3(1):2. https://doi.org/10.1186/s40170-014-0026-z
Leger AJ, Mosquea LM, Clayton NP, Wu IH, Weeden T, Nelson CA, Phillips L, Roberts E, Piepenhagen PA, Cheng SH, Wentworth BM (2013) Systemic delivery of a peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther 23(2):109–117. https://doi.org/10.1089/nat.2012.0404
El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, Alvarez-Erviti L, Sargent IL, Wood MJ (2012) Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 7(12):2112–2126. https://doi.org/10.1038/nprot.2012.131
Arambula JF, Ramisetty SR, Baranger AM, Zimmerman SC (2009) A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci U S A 106(38):16068–16073. https://doi.org/10.1073/pnas.0901824106
Coonrod LA, Nakamori M, Wang W, Carrell S, Hilton CL, Bodner MJ, Siboni RB, Docter AG, Haley MM, Thornton CA, Berglund JA (2013) Reducing levels of toxic RNA with small molecules. ACS Chem Biol 8(11):2528–2537. https://doi.org/10.1021/cb400431f
Ofori LO, Hoskins J, Nakamori M, Thornton CA, Miller BL (2012) From dynamic combinatorial ‘hit’ to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res 40(13):6380–6390. https://doi.org/10.1093/nar/gks298
Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A 106(44):18551–18556. https://doi.org/10.1073/pnas.0903234106
Childs-Disney JL, Hoskins J, Rzuczek SG, Thornton CA, Disney MD (2012) Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol 7(5):856–862. https://doi.org/10.1021/cb200408a
Childs-Disney JL, Parkesh R, Nakamori M, Thornton CA, Disney MD (2012) Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol 7(12):1984–1993. https://doi.org/10.1021/cb3001606
Childs-Disney JL, Stepniak-Konieczna E, Tran T, Yildirim I, Park H, Chen CZ, Hoskins J, Southall N, Marugan JJ, Patnaik S, Zheng W, Austin CP, Schatz GC, Sobczak K, Thornton CA, Disney MD (2013) Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun 4:2044. https://doi.org/10.1038/ncomms3044
Gareiss PC, Sobczak K, McNaughton BR, Palde PB, Thornton CA, Miller BL (2008) Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc 130(48):16254–16261. https://doi.org/10.1021/ja804398y
Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, Thornton CA, Disney MD (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc 131(28):9767–9779. https://doi.org/10.1021/ja9020149
Garcia-Lopez A, Llamusi B, Orzaez M, Perez-Paya E, Artero RD (2011) In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci U S A 108(29):11866–11871. https://doi.org/10.1073/pnas.1018213108
Chamberlain CM, Ranum LP (2012) Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise. Hum Mol Genet 21(21):4645–4654. https://doi.org/10.1093/hmg/dds306
Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, Swanson MS (2006) Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A 103(31):11748–11753. https://doi.org/10.1073/pnas.0604970103
Cai L, Koppanati BM, Bertoni C, Clemens PR (2014) In utero delivery of oligodeoxynucleotides for gene correction. Methods Mol Biol 1114:399–411. https://doi.org/10.1007/978-1-62703-761-7_26
Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y, Reyon D, Samara E, Gerli MFM, Klein AF, De Schrijver W, Tipanee J, Seneca S, Tulalamba W, Wang H, Chai YC, In’t Veld P, Furling D, Tedesco FS, Vermeesch JR, Joung JK, Chuah MK, VandenDriessche T (2018) Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res 46(16):8275–8298
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529(7587):490–495. https://doi.org/10.1038/nature16526
Acknowledgments
Some of the research described herein was conducted in the laboratories of TV and MC. This research was supported by grants from the Research Foundation of Flanders (FWO), Association Française contre les Myopathies (AFM), Scientific Fund Willy Gepts (WFWG, VUB), and King Boudewijn Foundation—Walter Pyleman Fund. YCC is supported by the IOF-GEAR grant (Vrije Universiteit Brussel); SD is supported by the PhD studentship of the Willy Gepts Fund (Wetenschappelijk Fonds Willy Gepts—Vrije Universiteit Brussel) and the King Boudewijn Foundation Walter Pyleman Fund. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667751 (MYOCURE).
Conflicts of Interest
The authors have no conflicts of interest to report.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chuah, M., Chai, Y.C., Dastidar, S., VandenDriessche, T. (2019). Gene Therapy and Gene Editing for Myotonic Dystrophy. In: Duan, D., Mendell, J. (eds) Muscle Gene Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-03095-7_30
Download citation
DOI: https://doi.org/10.1007/978-3-030-03095-7_30
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03094-0
Online ISBN: 978-3-030-03095-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)